GB2194885A - Pharmaceutical compositions containing vanadium - Google Patents
Pharmaceutical compositions containing vanadium Download PDFInfo
- Publication number
- GB2194885A GB2194885A GB08621756A GB8621756A GB2194885A GB 2194885 A GB2194885 A GB 2194885A GB 08621756 A GB08621756 A GB 08621756A GB 8621756 A GB8621756 A GB 8621756A GB 2194885 A GB2194885 A GB 2194885A
- Authority
- GB
- United Kingdom
- Prior art keywords
- vanadyl
- thiosulphate
- composition
- vanadium
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 8
- 229910052720 vanadium Inorganic materials 0.000 title claims description 28
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 title 1
- 239000000203 mixture Substances 0.000 claims abstract description 61
- -1 vanadyl compound Chemical class 0.000 claims abstract description 50
- DHCDFWKWKRSZHF-UHFFFAOYSA-L thiosulfate(2-) Chemical compound [O-]S([S-])(=O)=O DHCDFWKWKRSZHF-UHFFFAOYSA-L 0.000 claims abstract description 47
- 239000007864 aqueous solution Substances 0.000 claims abstract description 16
- TZKHCTCLSRVZEY-UHFFFAOYSA-L magnesium;dioxido-oxo-sulfanylidene-$l^{6}-sulfane Chemical compound [Mg+2].[O-]S([O-])(=O)=S TZKHCTCLSRVZEY-UHFFFAOYSA-L 0.000 claims abstract description 9
- 229940050410 gluconate Drugs 0.000 claims abstract description 8
- 238000011200 topical administration Methods 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 32
- 239000000243 solution Substances 0.000 claims description 28
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 claims description 27
- 125000005287 vanadyl group Chemical group 0.000 claims description 24
- 241000124008 Mammalia Species 0.000 claims description 20
- 238000002347 injection Methods 0.000 claims description 14
- 239000007924 injection Substances 0.000 claims description 14
- 239000002904 solvent Substances 0.000 claims description 12
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims description 6
- 208000011775 arteriosclerosis disease Diseases 0.000 claims description 6
- 201000011510 cancer Diseases 0.000 claims description 6
- 230000003340 mental effect Effects 0.000 claims description 5
- 230000001575 pathological effect Effects 0.000 claims description 5
- 208000011580 syndromic disease Diseases 0.000 claims description 5
- 239000003085 diluting agent Substances 0.000 claims description 4
- 238000010255 intramuscular injection Methods 0.000 claims description 4
- 230000003472 neutralizing effect Effects 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 238000001704 evaporation Methods 0.000 claims description 3
- 231100000252 nontoxic Toxicity 0.000 claims description 3
- 230000003000 nontoxic effect Effects 0.000 claims description 3
- 239000011734 sodium Substances 0.000 claims description 3
- WFHSPNCGYSVLCW-UHFFFAOYSA-K 2-hydroxypropane-1,2,3-tricarboxylate;oxovanadium(2+) Chemical compound [V+2]=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O WFHSPNCGYSVLCW-UHFFFAOYSA-K 0.000 claims description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 2
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 claims description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 claims description 2
- 239000003125 aqueous solvent Substances 0.000 claims description 2
- 239000011575 calcium Substances 0.000 claims description 2
- 229910052791 calcium Inorganic materials 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 150000007942 carboxylates Chemical class 0.000 claims description 2
- 239000002552 dosage form Substances 0.000 claims description 2
- 239000011261 inert gas Substances 0.000 claims description 2
- 238000010253 intravenous injection Methods 0.000 claims description 2
- 229910052744 lithium Inorganic materials 0.000 claims description 2
- 150000007522 mineralic acids Chemical class 0.000 claims description 2
- 239000002674 ointment Substances 0.000 claims description 2
- 150000007524 organic acids Chemical class 0.000 claims description 2
- 235000005985 organic acids Nutrition 0.000 claims description 2
- 239000011591 potassium Substances 0.000 claims description 2
- 229910052700 potassium Inorganic materials 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000000829 suppository Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 235000020357 syrup Nutrition 0.000 claims description 2
- 239000006188 syrup Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940095064 tartrate Drugs 0.000 claims description 2
- 238000011321 prophylaxis Methods 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 2
- 230000000259 anti-tumor effect Effects 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 238000011282 treatment Methods 0.000 description 12
- 230000002265 prevention Effects 0.000 description 6
- 150000001875 compounds Chemical class 0.000 description 5
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 4
- 239000002253 acid Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 238000006386 neutralization reaction Methods 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 150000004764 thiosulfuric acid derivatives Chemical class 0.000 description 3
- 241000282412 Homo Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000001175 calcium sulphate Substances 0.000 description 2
- 235000011132 calcium sulphate Nutrition 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 239000000395 magnesium oxide Substances 0.000 description 2
- CPLXHLVBOLITMK-UHFFFAOYSA-N magnesium oxide Inorganic materials [Mg]=O CPLXHLVBOLITMK-UHFFFAOYSA-N 0.000 description 2
- OUHCLAKJJGMPSW-UHFFFAOYSA-L magnesium;hydrogen carbonate;hydroxide Chemical compound O.[Mg+2].[O-]C([O-])=O OUHCLAKJJGMPSW-UHFFFAOYSA-L 0.000 description 2
- AXZKOIWUVFPNLO-UHFFFAOYSA-N magnesium;oxygen(2-) Chemical compound [O-2].[Mg+2] AXZKOIWUVFPNLO-UHFFFAOYSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 206010027654 Allergic conditions Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000002052 anaphylactic effect Effects 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 229910052785 arsenic Inorganic materials 0.000 description 1
- RQNWIZPPADIBDY-UHFFFAOYSA-N arsenic atom Chemical compound [As] RQNWIZPPADIBDY-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 229960005069 calcium Drugs 0.000 description 1
- 239000004227 calcium gluconate Substances 0.000 description 1
- 229960004494 calcium gluconate Drugs 0.000 description 1
- 235000013927 calcium gluconate Nutrition 0.000 description 1
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 230000002079 cooperative effect Effects 0.000 description 1
- 208000029039 cyanide poisoning Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000855 fungicidal effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 229910052737 gold Inorganic materials 0.000 description 1
- 239000010931 gold Substances 0.000 description 1
- 230000000749 insecticidal effect Effects 0.000 description 1
- 229940079905 intestinal adsorbents bismuth preparations Drugs 0.000 description 1
- 229910001425 magnesium ion Inorganic materials 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 231100000404 nontoxic agent Toxicity 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000035939 shock Effects 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- UUUGYDOQQLOJQA-UHFFFAOYSA-L vanadyl sulfate Chemical compound [V+2]=O.[O-]S([O-])(=O)=O UUUGYDOQQLOJQA-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Inorganic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Pharmaceutical compositions comprising a vanadyl compound and a thiosulphate, preferably together with a pharmaceutical carrier, in forms for oral, parenteral, rectal or topical administration, have anti- arteriosclerotic and anti-tumour activity. Suitable compositions are aqueous solutions of vanadyl gluconate and magnesium thiosulphate.
Description
SPECIFICATION
Pharmaceutical compositions
The present invention relates to pharmaceutical compositions for the prevention and treatment of various pathological conditions.
Vanadyl compounds, which contain the VO radical, have been rarely used in pharmacology. The suggestion in U.S. Patent No.
2135111 that vanadyl lactate and possibly other vanadyl carboxylates have antiseptic, and in particular insecticidal and fungicidal properties, does not appear to have led to the widespread use of such compounds for the stated purposes.
Thiosulphates, on the other hand, find pharmacological application e. g. for the treatment of cyanide poisoning, allergic conditions and drug sensitization caused by gold, arsenic, mercury or bismuth preparations. A magnesium thiosulphate preparation in the form of tablets or injectable aqueous solutions is available on the market and is stated to be indicated for shock, medicament intolerance, as well as for anaphylactic conditions due to serums or vaccines.
The present inventor has surprisingly found that the combination of a vanadyl compound and a thiosulfate is effective for the treatment, and so far as can be presently ascertained the prevention, of a variety of pathological conditions, inciuding conditions quite different from those for which thiosulphates alone have been suggested, or for which certain vanadyl compounds alone have been proposed.
The present invention accordingly provides a novel composition of matter which comprises an admixture of a vanadyl compound and a thiosulfate, as well as a pharmaceutical composition which comprises as active ingredients, a vanadyl compound and a thiosulfate, together with an inert carrier, diluent or excipient. In either case, the composition may comprise, for example, 1 part vanadyl compound and from about 100 to about 20, 000 parts thiosulphate, by weight.
The invention also provides processes for preparing the compositions, details of which wil be given infra.
The compositions of the invention are in particular useful for the treatment or prevention of such diverse conditions as arteriosclerosis and malignant tumours in mammals, and mental syndromes in the elderly.
The pharmaceutical compositions of the present invention may be presented in a form suitable for oral, parenteral, rectal or topical administration, and may be in unit dosage form. The compositions may be formulated as e.g. tablets, capsules, powders, syrups, suspensions, orally administrable solutions, injectable solutions (in particular such solutions which are suitable for intramuscular or intravenous injection, including especially aqueous solutions), ointments, suppositories or any other pharmaceutical form.
In general terms, any carrier, diluent or excipient known in pharmacology may be used to formulate the pharmaceutical compositions of the invention. It should be noted that the invention moreover includes compositions containing the two necessary components even in the absence of such adjuvants; such compositions may be used for administration in their own right, but will more generally be used as concentrates, to be made up as required with a carrier, diluent or excipient.
The vanadyl compound used in the compositions of the invention may be selected from vanadyl salts with non-toxic inorganic or organic acids. Water-soluble vanadyl salts are preferred, and more particularly vanadyl salts which are selected from vanadyl lactate, vanadyl tartrate, vanadyl citrate and a vanadyl sugar-derived carboxylate, such as vanadyl gluconate. Inorganic salts such as vanadyl phosphate, are also suitable, however.
The thiosulphate may be, e.g., selected from lithium, sodium, potassium, calcium and magnesium thiosulfates; magnesium thiosulphate is presently the preferred thiosulphate.
The processes available for the preparation of the compositions of the invention are well known to those skilled in the art, and the details of such preparative processes given herein are by way of exemplification only.
For example, the compositions may be made by a process which comprises mixing the dry components. Alternatively, the components maye be mixed in presence of a solvent, followed by removal of the solvent. In yet another alternative, the preparative process may comprise mixing the components, at least one of which is in the form of a solution, followed by removal of the solvent or solvents, where necessary or desired.
It will be appreciated that thiosulphates are acid-sensitive compounds, so that it will be preferable to take care to avoid acid conditions, when preparing the compositions of the invention. One way of avoiding acid conditions, when using a solution of vanadyl compound, is to neutralize such solution, e. g. to a pH of about 7.0 to about 7.5, prior to mixing with the thiosulphate component. Any suitable non-toxic agent may be used for the neutralization step; non-limiting examples are sodium bicarbonate, magnesium oxide and magnesium hydroxycarbonate.
The thus-neutralized solution of vanadyl compound may be, according to one procedure, mixed with a solution of the thiosulphate. According to an alternative procedure, the neutralized solution may be evaporated, and a thiosulphate solution mixed with the residue. The solutions used in these procedures are preferably aqueous solutions.
Following the neutralization step, it will be desirable to clarify the solution of vanadyl compound by removing any insoluble matter, before proceding further, whatever the exact nature of the subsequent step or steps may be.
Thus, a process for preparing the compositions of the invention may comprise neutralizing to a pH of about 7.0 to about 7.5, an aqueous solution of the vanadyl compound, removing any insoluble matter, evaporating the thus-neutralized and clarified solution, maintaining the residue in an inert gas atmosphere for any desired period of time, and then mixing with it an aqueous solution of the thiosulphate, followed by the optional step of removing the aqueous solvent if desired.
The compositions of the invention are useful for treating arteriosclerosis or malignant tumours in mammals, as well as mental syndromes in the elderly. The term "mammals" is intended to convey both humans and nonhuman mammals such as horses and cattle.
The amounts of the active components in the compositions of the invention used to treat the foregoing conditions will normally be such as to provide a daily dosage of from about 0.3 to about 18.0 mg. vanadium as vanadyl compound and from about 0.2 to about 5.0 g. thiosulphate, when administration is by injection. Owing to the lower absorption of vanadyl compound when administered orally, the quantity of vanadium as vanadyl administered by the oral route can be considerably increased, e.g. up to about 40 mg. and the quantity of thiosulphate can be correspondingly increased e.g. up to about 10.0 g. It will be apparent to those skilled in the art how the quantities of active ingredients are adjusted when other forms of administration are used. Such quantities of the active compounds may conveniently be administered in the form of 1 to 6 unit dosages, daily.The
Examples, infra, show an advantageous rate of success, when the pathological conditions mentioned above have been treated with the compositions of the invention.
It is presently believed that the compositions of the invention are effective in preventing or delaying the incidence of the pathological conditions mentioned above. This belief is supported by preliminary clinical studies carried out by the inventor. However, it will be appreciated by those skilled in the art that it is considerably more difficult to establish prevention of a disease or condition which has not yet occurred, than it is to show that an existing disease or condition has been cured or at least ameliorated, by treatment.
As is known, the quantities of therapeutic agents useful for prevention are usually a fraction of the quantities useful for treating a condition. It is presently believed that the amounts of the active components in the compositions of the invention which will be useful to prevent the foregoing conditions will normally be such as to provide a daily dosage of from about 0.06 to about 9.0 mg. vanadium as vanadyl compound and from about 0.04 to about 2.5 g. thiosulphate, when administration is by injection. Owing to the lower absorption of vanadyl compound when administered orally, the quantity of vanadium as vanadyl administered by the oral route can be considerably increased, e.g. up to about 13.3 mg. and the quantity of thiosulphate can be correspondingly increased e.g. up to about 3.3 g.It will be apparent to those skilled in the art how the quantities of active ingredients are adjusted when other forms of administration are used. As with the compositions of the invention to be used for treatment, such quantities of the active compounds may conveniently be administered in the form of 1 to 6 unit dosages, daily.
It will be appreciated by those skilled in the art that the actual daily dosages of the compositions of the invention to be administered to a patient or to a non-human mammal will lie entirely within the discretion of the physician or veterinarian, as the case may be.
Whether the daily dosage for treatment of a condition, or prevention of a condition, will lie within the ranges of quantities stated above, or whether the daily dosage will be above or below such ranges, will depend on such factors as the sex and maturity of the patient or non-human mammal, its weight, and where treatment especially is concerned, the nature and severity of the condition itself.
It will be evident, for example, that taking the ranges of quantities described above as generally including typical daily dosages for an adult human male of average weight (i.e.
about 70 kg.), an adult female or child (or for that matter a non-human mammal of lesser weight than the average human male) is, other factors being equal, likely to require a daily dosage of the active components in the lower part of these ranges, or below the minima of one or both of these ranges, whereas the converse would be expected when dealing with e.g. either humans or non-human mammals which are heavier than the average human male.
Moreover, it will be evident to those skilled in the art that administering these two components separately would in a sense be an obvious equivalent of administering these components as part of the same composition. Nevertheless, besides the convenience of using a single type of dosage unit comprising both active components, it is believed that such separate administration is likely to be relatively inferior.Thus, while the present invention is not to be restricted by any theory of the manner in which the components act in the body, it is possible that one component acts to promote the activity of the other component, or perhaps that the two components act synergistically. (For example, it could be postulated that vanadyl compounds activate aerobic metabolism and in particular respiration, at the cellular level, and that thiosulphate enables the vanadyl compounds to be effective in low and non-toxic levels).
Any such manner of cooperative action would require the two components to be present in the optimum concentration together, whereas a time lag between the administration of the components is likely to act so as to minimize the possibility that such optimum concentration would be obtained and to require higher doses of the active ingredients, which could undesirably approach the toxic limits.
The invention will now be illustrated by the following non-limitative Examples. In all cases the vanadyl gluconate solutions were obtained by reacting together vanadyl sulphate and calcium gluconate solutions, removing the thusformed calcium sulphate by filtration or centrifugation, and recovering the filtrate or supernate containing vanadyl gluconate. The presence of negligible quantities of calcium sulphate and/or glutonate in the filtrate or supernate does not adversely affect the compositions of the invention. The neutralization step is effected using sodium bicarbonate, magnesium oxide or magnesium hydroxycarbonate, followed if necessary by clarification by filtration or centrifugation. The presence of small quantities of sodium or magnesium ions in the thus-obtained filtrate or supernate does not adversely affect the compositions of the invention.
EXAMPLE I
Daily injections of 10 ml. 12% magnesium thiosulphate aqueous solution, to which had been added neutralized vanadyl gluconate aqueous solution containing 1.5 mg. vanadium as vanadyl radical, were administered to 10 patients suffering from various forms of arteriosclerosis. In all cases there was observed a marked and steady improvement in their clinical condition after 1-3 months of treatment.
The injections were given intramuscularly in 8 cases and intravenously in 2 cases. No side effects were observed.
EXAMPLE II
Daily intramuscular injections of 10 ml. 12% magnesium thiosulphate aqueous solution, to which had been added neutralized vanadyl gluconate aqueous solution containing 3. 0 mg.
vanadium as vanadyl radical, were administered to 7 patients suffering from various forms of malignant tumours (1 breast tumour, 3 prostate tumours, 1 multiple myeloma and 2 bladder tumors, in different patients). All the patients were regarded as terminal or preterminal, and previous treatments were non-beneficial. There was observed a marked improvement in all cases after 2-3 weeks of treatment. Complete clinical recovery was observed in 4 cases after 4 months. No side effects were observed.
EXAMPLE III
Daily intramuscular injections of 10 ml. 12% magnesium thiosulphate aqueous solution, to which had been added neutralized vanadyl gluconate aqueous solution containing 5.0 mg.
vanadium as vanadyl radical, were administered to 10 elderly patients suffering from organic geriatric mental syndromes. After one month of treatment, there was observed a marked improvement in 7 cases and a slight improvement in 3 cases. No side effects were observed.
Claims (50)
1. A novel composition of matter which comprises an admixture of a vanadyl compound and a thiosulfate.
2. A composition according to claim 1, which comprises part vanadyl compound and from about 100 to about 20,000 parts thiosulphate, by weight.
3. A pharmaceutical composition which comprises as active ingredients, a vanadyl compound and a thiosulfate, together with an inert carrier, diluent or excipient.
4. A composition according to claim 3, which comprises part vanadyl compound and from about 100 to about 20,000 parts thiosulphate, by weight.
5. A composition according to either claim 3 or claim 4, which is in a form suitable for oral, parenteral, rectal or topical administration.
6. A composition according to claim 5, which is in unit dosage form.
7. A composition according to either claim 6 or claim 7, which is in the form of tablets, capsules, powders, syrups, suspensions, orally administrable solutions, injectable solutions ointments, suppositories or any other pharmaceutical form.
8. A composition according to claim 7, which is in the form of a solution suitable for intramuscular or intravenous injection.
9. A composition according to claim 8, which is an injectabie aqueous solution.
10. A composition according to any of the preceding claims, wherein the vanadyl compound is selected from vanadyl salts with non-toxic inorganic or organic acids.
11. A composition according to claim 10, wherein said vanadyl salts are water-soluble.
12. A composition according to claim 11, wherein said vanadyl salts are selected from the group consisting of vanadyl lactate, vanadyl tartrate, vanadyl citrate and a vanadyl sugarderived carboxylate.
13. A composition according to claim 12, which comprises vanadyl gluconate.
14. A composition according to any of the preceding claims, wherein the thiosulphate is selected from the group consisting of lithium, sodium, potassium, calcium and magnesium thiosulphates.
15. A composition according to claim 14, wherein the thiosulphate is magnesium thiosulphate.
16. A process for preparing the composition of claim 1 or claim 2, which comprises mixing the dry components.
17. A process for preparing the composition of claim 1 or claim 2, which comprises mixing the components in presence of a solvent, followed by removal of the solvent.
18. A process for preparing the composition of claim 1 or claim 2, which comprises mixing the components, at least one of which is in the form of a solution, followed by removal of the solvent or solvents.
19. A process for preparing the composition of any of claims 3 to 15, which comprises mixing the dry components.
20. A process for preparing the composition of any of claims 3 to 15, which comprises mixing the components in presence of a solvent, and if necessary or desired, removing the solvent.
21. A process for preparing the composition of any of claims 3 to 15, which comprises mixing the components, at least one of which is in the form of a solution, and if necessary or desired, removing the solvent or solvents.
22. A process according to claim 21, which comprises neutralizing to a pH of about 7.0 to about 7.5, a solution of the vanadyl compound, and then mixing the thus-neutralized solution with a solution of the thiosulphate.
23. A process according to claim 21, which comprises neutralizing to a pH of about 7.0 to about 7.5, a solution of the vanadyl compound, evaporating the thus-neutralized solution and then mixing with the residue, a solution of the thiosulphate.
24. A process according to any of claims 21 to 23, in which the said solutions are aqueous solutions.
25. A process for preparing the composition of any of claims 3 to 15, which comprises neutralizing to a pH pf about 7.0 to about 7.5, an aqueous solution of the vanadyl compound, removing any insoluble matter, evaporating the thus-neutralized and clarified solution, maintaining the residue in an inert gas atmosphere for any desired period of time, and then mixing it with an aqueous solution of the thiosulphate, followed by the optional step of removing the aqueous solvent if desired.
26. A composition according to any of claims 3 to 15, which is in the form of dosage units containing the active ingredients in amounts such that one to six such units contain from about 0.3 to about 18.0 mg. vanadium as vanadyl compound and from about 0.2 to about 5.0 g. thiosulphate, for administration by injection, the said maxima being increased for oral administration up to about 40 mg. vanadium as vanadyl comound and up to about 10.0 g thiosulphate.
27. A composition according to any of claims 3 to 15, which is in the form of dosage units containing the active ingredients in amounts such that one to six such units contain from about 0.06 to about 9.0 mg. vanadium as vanadyl compound and from about 0.04 to about 2.5 g. thiosulphate, for administration by injection, the said maxima being increased up to about 13.3 mg. vanadium as vanadyl comound and up to about 3.3 g thiosulphate for oral administration.
28. A composition as defined in either claim 26 or claim 27, which has been prepared by the process according to any of claims 16 to 25.
29. A method for treating arteriosclerosis in mammals, which comprises administering to mammals diagnosed for arteriosclerosis, a composition according to any of claims 3 to 15.
30. A method according to claim 29, wherein the composition and the amount thereof administered is such that per day there are administered from about 0.3 to about 18.0 mg. vanadium as vanadyl compound and from about 0.2 to about 5.0 g.
thiosulphate, per mammal, for administration by injection, the said maxima being increased up to about 40 mg. vanadium as vanadyl comound and up to about 10 g. thiosulphate for oral administration.
31. A method for treating malignant tumours in mammals, which comprises administering to mammals diagnosed for malignant tumors, a composition according to any of claims 3 to 15.
32. A method according to claim 31, wherein the composition and the amount thereof administered is such that per day there are administered from about 0.3 to about 18.0 mg. vanadium as vanadyl compound and from about 0.2 to about 5.0 g.
thiosulphate, per mammal, for administration by injection, the said maxima being increased up to about 40 mg. vanadium as vanadyl compound up to about 10 g. thiosulphate for oral administration.
33. A method for treating mental syndromes in the elderly, which comprises administering to patients falling into this category, a composition according to any of claims 3 to 15.
34. A method according to claim 33, wherein the composition and the amount thereof administered is such that per day there are adminis tered from about 0.3 to about 18.0 mg. vanadium as vanadyl compound and from about 0.2 to about 5.0 g.
thiosulphate, per patient, for administration by injection, the said maxima being increased up to about 40 mg. vanadium as vanadyl comound and up to about 10 g. thiosulphate for oral administration.
35. A method for preventing malignant tumours in mammals, which comprises administ ering thereto, a composition according to any of claims 3 to 15.
36. A method according to claim 35, wherein the composition and the amount thereof administered is such that per day there are administered from about 0.06 to about 9.0 mg. vanadium as vanadyl compound and from about 0.04 to about 2.5 g.
thiosulphate, per mammal, for administration by injection, the said maxima being increased up to about 13.3 mg. vanadium as vanadyl comound and up to about 3.3 g. thiosulphate for oral administration.
37. A method for preventing arteriosclerosis in mammals, which comprises administering thereto, a composition according to any of claims 3 to 15.
38. A method according to claim 37, wherein the composition and the amount thereof administered is such that per day there are administered from about 0.06 to about 9.0 mg. vanadium as vanadyl compound and from about 0.04 to about 2.5 g.
thiosulphate, per mammal, for administration by injection, the said maxima being increased up to about 13.3 mg. vanadium as vanadyl comound and up to about 3.3 g. thiosulphate for oral administration.
39. A method for preventing mental syndromes in the elderly, which comprises administering thereto, a composition according to any of claims 3 to 15.
40. A method according to claim 39, wherein the composition and the amount thereof administered is such that per day there are administered from about 0.06 to about 9.0 mg. vanadium as vanadyl compound and from about 0.04 to about 2.5 g.
thiosulphate, per patient, for administration by injection, the said maxima being increased up to about 13. 3 mg. vanadium as vanadyl comound and up to about 3.3 g. thiosulphate for oral administration.
41. A method for treating pathological conditions in mammals, which comprises administering to the mammals therapeutically effective amounts of a vanadyl compound and a thiosulphate.
42. A method for the prophylactic treatment of mammals, which comprises administering to the mammals prophylactically effective amounts of a vanadyl compound and a thiosulphate.
43. A method according to claim 41, which comprises administering to the mammals a daily dosage falling within the ranges of from about 0.3 to about 18.0 mg. vanadium as vanadyl compound and from about 0.2 to about 5.0 g. thiosulphate, for administration by injection, the said maxima being increased up to about 40 mg. vanadium as vanadyl comound and up to about 10 g. thiosulphate for oral administration.
44. A method according to claim 42, which comprises administering to the mammals a daily dosage falling within the ranges of from about 0.06 to about 9.0 mg. vanadium as vanadyl compound and from about 0.04 to about 2.5 9. thiosulphate, for administration by injection, the said maxima being increased up to about 13.3 mg. vanadium as vanadyl comound and up to about 3.3 g. thiosulphate for oral administration.
45. A composition according to any of claims 1 to 15, and 26 to 28, substantially as hereinbefore described.
46. A composition according to any of claims 1 to 15, and 26 to 28, substantially as hereinbefore described in any of the Examples.
47. A process according to any of claims 16 to 25, substantially as hereinbefore described.
48. A process according to any of claims 16 to 25, substantially as hereinbefore described in any of the Examples.
49. A method according to any of claims 29 to 44, substantially as hereinbefore described.
50. A method according to any of claims 29 to 44, substantially as hereinbefore described in any of the Examples.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08621756A GB2194885A (en) | 1986-09-10 | 1986-09-10 | Pharmaceutical compositions containing vanadium |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB08621756A GB2194885A (en) | 1986-09-10 | 1986-09-10 | Pharmaceutical compositions containing vanadium |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| GB8621756D0 GB8621756D0 (en) | 1986-10-15 |
| GB2194885A true GB2194885A (en) | 1988-03-23 |
Family
ID=10603936
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB08621756A Withdrawn GB2194885A (en) | 1986-09-10 | 1986-09-10 | Pharmaceutical compositions containing vanadium |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB2194885A (en) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4336642A1 (en) * | 1993-10-22 | 1995-04-27 | Deutsches Rheuma Forschungszen | Use of vanadium compounds for the production of pharmaceuticals with an antiviral action |
| WO1995019177A1 (en) * | 1994-01-18 | 1995-07-20 | Mount Sinai Hospital Corporation | Vanadate compounds for the treatment of proliferative disorders, metastases and drug resistant tumors |
| US5871779A (en) * | 1994-01-18 | 1999-02-16 | Mount Sinai Hospital Corporation | Treatment of arthropathies with vanadate compounds or analogues thereof |
| US6506411B2 (en) | 1993-07-19 | 2003-01-14 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
| US6921523B2 (en) | 2003-10-14 | 2005-07-26 | Tessenderlo Kerley, Inc. | Magnesium thiosulfate solution and process for preparing same |
| US7686963B2 (en) | 2004-11-16 | 2010-03-30 | Tessenderlo Kerley, Inc. | Magnesium thiosulfate as ozone quencher and scrubber |
-
1986
- 1986-09-10 GB GB08621756A patent/GB2194885A/en not_active Withdrawn
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6506411B2 (en) | 1993-07-19 | 2003-01-14 | Angiotech Pharmaceuticals, Inc. | Anti-angiogenic compositions and methods of use |
| DE4336642A1 (en) * | 1993-10-22 | 1995-04-27 | Deutsches Rheuma Forschungszen | Use of vanadium compounds for the production of pharmaceuticals with an antiviral action |
| WO1995019177A1 (en) * | 1994-01-18 | 1995-07-20 | Mount Sinai Hospital Corporation | Vanadate compounds for the treatment of proliferative disorders, metastases and drug resistant tumors |
| US5843481A (en) * | 1994-01-18 | 1998-12-01 | Mount Sinai Hospital Corporation | Treatment of proliferative disorders, metastasaes, and drug resistant tumors with vanadate compounds and derivatives or analogues thereof |
| US5871779A (en) * | 1994-01-18 | 1999-02-16 | Mount Sinai Hospital Corporation | Treatment of arthropathies with vanadate compounds or analogues thereof |
| US6921523B2 (en) | 2003-10-14 | 2005-07-26 | Tessenderlo Kerley, Inc. | Magnesium thiosulfate solution and process for preparing same |
| US7686963B2 (en) | 2004-11-16 | 2010-03-30 | Tessenderlo Kerley, Inc. | Magnesium thiosulfate as ozone quencher and scrubber |
Also Published As
| Publication number | Publication date |
|---|---|
| GB8621756D0 (en) | 1986-10-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5045316A (en) | Pharmaceutical compositions and their use | |
| CA2421410C (en) | Iron compositions | |
| US2957806A (en) | Process for raising blood serum iron levels and controlling anemia | |
| WO1999007699A1 (en) | Immuno-modulator exhibiting anti-microbial and anti-mycobacterial activities, method for producing the same and pharmaceutical preparation for treating mycobacterioses as well as lung chronic and non specific conditions, sexually transmitted diseases and the resulting immuno-deficiency | |
| LONGCOPE et al. | The use of bal (British anti-lewisite) in the treatment of the injurious effects of arsenic, mercury and other metallic poisons | |
| GB2194885A (en) | Pharmaceutical compositions containing vanadium | |
| IE54475B1 (en) | Process for the production of an iron-selenuim trace element solution | |
| McEnery et al. | Treatment of acute iron ingestion with deferoxamine in 20 children | |
| Klein | Tacrolimus rescue in liver transplant patients with refractory rejection or intolerance or malabsorption of cyclosporine | |
| US4591503A (en) | Composition for improved absorption of 2A cations and gold comprising yeast or Lactobacillus | |
| JPH032872B2 (en) | ||
| EP0938900B1 (en) | Preventives/remedies for stomatitis | |
| US4218471A (en) | Process for the treatment of humans suffering from undesired urotoxic side effects caused by cytostatically active alkylating agents | |
| JP3253878B2 (en) | Formulations for iron chelation, methods of preparing the same and methods of treating Mediterranean anemia | |
| EP0372676A1 (en) | Therapeutic preparation and method | |
| US3062719A (en) | Trisodium calcium diethylenetriaminepentaacetic acid, compositions containing the same, and the use thereof | |
| EP0476391B1 (en) | Anti-AIDS virus composition containing cepharanthine as active compound | |
| KR20020031404A (en) | Blood plasma replacement solution | |
| JPS5938207B2 (en) | Kidney disease treatment | |
| Cohen et al. | Nitrogen mustard in treatment of rheumatoid arthritis | |
| US4029771A (en) | Composition for the treatment of bacterial-intestinal infections | |
| CA2259997C (en) | Remedies and preventives for stomatitis | |
| Ciba Pharmaceutical Company | Deferoxamine mesylate (Desferal mesylate); A specific iron‐chelating agent for treating acute iron intoxication | |
| GREENBERG et al. | Iron Toxicity | |
| MRAZEK et al. | Palliative chemotherapy of solid tumors with nitromin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| WAP | Application withdrawn, taken to be withdrawn or refused ** after publication under section 16(1) |